Descripción de la empresa
Quaker Chemical Corporation, operating commercially under the name Quaker Houghton, specializes in the development, production, and marketing of formulated specialty chemical products alongside chemical management services tailored for heavy industrial and manufacturing applications. The enterprise functions within the Basic Materials sector, specifically targeting the Specialty Chemicals industry, where it supplies essential industrial process fluids to a global client base. This operational scope supports a substantial organization employing approximately 4,700 individuals and maintaining a total market capitalization of $2.12 billion. With annual revenues reaching $1.89 billion, the company's financial scale positions it as a significant player in the specialty chemicals landscape, indicating a robust operational footprint capable of sustaining large-scale production and distribution networks. The combination of its extensive workforce and multi-billion dollar revenue stream reflects the capital intensity and market reach required to compete effectively in the global industrial fluids market.
Salud financiera
The company reported total revenue of $1.89 billion for the trailing twelve months, while net income stood at -$2,468,000, and EBITDA was calculated at $286.79 million. The substantial disparity between the positive EBITDA and the negative net income highlights a cost structure where interest expenses or other non-operating costs significantly erode profitability, resulting in a loss despite healthy operational cash generation. Free cash flow remains positive at $91.07 million, which provides the organization with essential financial flexibility to fund capital expenditures, manage working capital, or pursue strategic initiatives without relying on external financing. The gross margin stands at 36.3%, indicating that the company retains a significant portion of revenue after direct production costs, while the operating margin of 9.0% suggests moderate efficiency in managing overhead and administrative expenses. However, the profit margin is -0.1%, a metric driven by the aforementioned non-operating charges that prevent the conversion of operating profits into bottom-line earnings. On the liquidity front, cash reserves of $179.84 million are contrasted against total debt of $905.85 million, creating a leverage profile that warrants scrutiny. The debt-to-equity ratio is recorded at 65.81, signifying a highly leveraged balance sheet where debt obligations substantially exceed shareholder equity. Despite this high leverage, the current ratio of 2.42 demonstrates strong short-term liquidity, indicating that current assets are more than twice the value of current liabilities, ensuring the ability to meet immediate financial obligations. Return on equity is -0.2%, reflecting the impact of the net loss on shareholder value, whereas return on assets is 4.5%, suggesting that the asset base is generating positive cash flows before the allocation of capital costs and interest.
Evaluación de valoración
The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E is 13.13, implying that analysts project a significant improvement in earnings that would allow for a traditional multiple-based valuation in the near future. The price-to-book ratio is 1.54, which indicates that the market values the company at a 54% premium over its net asset value, suggesting confidence in the brand, intangible assets, or future cash-generating potential beyond the book value. Alternative valuation metrics provide additional context, with the price-to-sales ratio at 1.12 and the EV/EBITDA multiple at 9.94, both of which suggest the stock is priced at a level comparable to or slightly below historical averages for the specialty chemicals sector given the forward-looking EBITDA. Regarding trading ranges, the 52-week high is $183.01 and the low is $95.91; without a specific current share price provided in the source data, the precise percentage distance from these bounds cannot be calculated, though the range defines the volatility boundaries experienced by the stock over the last year. The beta value is 1.42, which signifies that the stock's price volatility is 42% higher than the broader market, indicating that investors should expect more pronounced swings in share price relative to general market movements during periods of economic fluctuation.
Growth & Income
Revenue growth for the year-over-year period is 5.5%, while earnings growth is reported at 48.6%, demonstrating that earnings are expanding at a pace more than eight times faster than revenue. This divergence typically implies that the company is benefiting from margin expansion, cost controls, or one-time gains that are not yet reflected in the top line, although the negative net income complicates the direct interpretation of earnings growth in the traditional sense. As a dividend payer, the company offers a yield of 1.7% with a payout ratio of 35.6%, a figure that suggests the current dividend is funded primarily by free cash flow rather than net income, given the negative earnings. This payout structure indicates a degree of sustainability contingent on the maintenance of strong cash flows, as the payout ratio is not constrained by the traditional net income denominator. The overall growth and income profile presents a mix of moderate revenue expansion, accelerated earnings trajectory, and a yield supported by cash generation rather than accounting profits.